Gamifant® (emapalumab-lzsg) – New indication
June 28, 2025 - Sobi announced the FDA approval of Gamifant (emapalumab-lzsg), for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still’s disease, including systemic juvenile idiopathic arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.